adverse effects generally limited in severity and duration. However, because patients are more frequently living longer due to improvements in control of the primary disease, they become more susceptible to serious and permanent toxic effects from WBRT that are still poorly understood, such as neurocognitive deterioration and cerebellar dysfunction. 2, 6, 18 In an attempt to avoid late consequences of WBRT, SRS alone or in conjunction with WBRT has been used to treat brain metastases. [9] [10] [11] [14] [15] [16] 19, 21 The results of the Radiation Therapy Oncology Group 9508 randomized trial and a recent study by Aoyama and colleagues 2 have shown that SRS and WBRT lead to better long-term intracranial disease control for many subgroups of patients. However, the sequence of these two treatments remains unclear. 1, 7 The current study assesses the early tumor volumetric responses following GKS. This pattern may have implications in terms of the optimal order of delivery of radiosurgery and WBRT in the overall management of patients with brain metastasis.
Methods

Patient Inclusion
From March 2002 to August 2006, 141 patients with brain metastases received staged treatment with GKS (Leksell Gamma Knife, Elekta Instrument AB) at the University of Virginia and had early follow-up MR imaging (< 1 month after GKS). Patients were included in this study if they had follow-up MR imaging within 30 days or less (mean neuroimaging follow-up interval = 13 days) from the initial GKS and had lesions measuring 0.5 cm 3 or greater. The criterion of a minimum tumor volume of 0.5 cm 3 was used to assure reasonably accurate tumor volumetry. 22 Eighty-two patients harboring 134 metastatic brain lesions met both the MR imaging and minimum tumor volume criteria. The metastatic tumor volumes varied between 0.5 cm 3 and 24 cm 3 (mean 4.3 cm 3 ) and were of diverse histopathological types ( Table 1) . The patient population was composed of 46 males and 36 females; the median age was 59 years (range 37-84 years); the KPS score was ≥ 70 in all patients (mean score = 80; Table 1 ).
The GKS technique used is as described in the paper by Steiner and colleagues. 23 For both treatment and follow-up imaging the MR imaging protocol consisted of gadolinium-enhanced, T1-weighted, spin echo axial and coronal sequences with contiguous 3 mm slices. The GKS parameters that were used are summarized in Table 2 .
Assessment of Tumor Volumetry
Initial tumor volumetry was determined using the functionality included in the Gamma Plan software (versions 5.33 and 5.34, Elekta Instruments AB). Follow-up volumetry of the treated metastatic deposits was measured using ImageJ software (version 1.31, National Institutes of Health). The lesions were classified into 3 different categories: enlarged (> 15% volume increase), stable (followup volume ± 15% of the initial volume), or decreased (> 15% volume decrease). The measurements were always performed by 2 different observers. If discordant tumor volumetric assessments were obtained, a third observer assessment was performed and the images were reviewed by a neuroradiologist. For analytical purposes the mean tumor follow-up volume was used. The volumetry was performed in a fashion in which the individuals were blinded to carcinoma histopathology and additional adjuvant treatment (such as chemotherapy, WBRT, and others).
Lesion volumes as they appear in MR imaging sequences are frequently calculated from the sum of the areas contoured on each slice, multiplied by the slice thickness. Snell and associates, 22 using the trapezoidal rule formula, concluded that with accurate delineation on at least 5 slices, volumetry would provide an expected error rate of 10% or less. We purposely considered for measurements only those lesions of at least 0.5 cm 3 whose delineation would encompass a minimum of 3 slices, and we assumed a measurement error of ± 15%.
Statistical Analysis
All statistical analyses were performed using the SPSS statistical package (version 14.0, SPSS, Inc.). Along with descriptive statistics, multinomial logistic regression was used to evaluate the prognostic significance of several proposed factors on the probability of a tumor being classified as enlarged, decreased, or stable. Statistical significance was defined as a probability value ≤ 0.05. All variables were simultaneously entered into the regression model. Proposed factors that could be predictive of volumetric change on radiographic follow-up included peripheral isodose, peripheral dose, total number of intracranial lesions, brain tumor volume on the day of GKS, WBRT (yes or no), chemotherapy (yes or no), initial KPS score, age, and sex.
Results
One hundred thirty-four lesions were measured in 82 patients. Sixty-four lesions decreased in volume (47.8%), 55 were stable (41.0%), and 15 (11.2%) increased in volume (Table 3) . Among the metastatic lesions that increased in volume, the mean volume increase was + 45.7%; there were 9 melanomas, 3 NSCLCs, 2 esophageal carcinomas, and 1 renal cell carcinoma (Table 3) . Among the 64 lesions that decreased in volume, the mean volume change was −41.7%. Of those that decreased in volume, there were 26 NSCLCs, 21 breast carcinomas, 7 melanomas, 4 small cell lung carcinomas, 3 esophageal carcinomas, 2 ovarian carcinomas, and 1 rectal carcinoma (Table 3) . Fifty-five lesions were considered stable from a volumetric standpoint, and the mean volume change was −1.1%; among them we found 27 NSCLCs, 15 melanomas, 9 breast carcinomas, 2 colon carcinomas, 1 small cell lung carcinoma, and 1 renal cell carcinoma (Table 3) .
A multivariate analysis failed to identify any of the proposed prognostic factors (sex, age, KPS score, tumor volume on the day of treatment, peripheral isodose, peripheral dose, total number of intracranial lesions, previous WBRT, and previous chemotherapy) as statistically significant with regard to volumetric outcome.
Metastases from breast carcinomas were the most responsive, with 100% either decreasing (70%) or remaining stable (30%). Of the metastatic deposits from NSCLCs, 46.4% decreased and 48.2% were stable. Melanomas were the least responsive tumors, with only 22.6% shrinking in the first month (Fig. 1 ).
An analysis of variance was used to evaluate differences in the mean percentage change in tumor volume in 117 NSCLC, breast carcinoma, and melanoma histopathological types (other histopathological types were excluded due to the small number of these types). The overall analysis showed that there is a significant difference in percentage tumor change according to histopathological type (p < 0.001): post hoc tests (using the Bonferroni method) showed a significant difference between melanomas and breast carcinomas (p < 0.001) and between melanomas and NSCLCs (p = 0.016).
Local tumor control and tumor shrinkage varied as a function of initial tumor volume (Fig. 2) . In general, tumors that were > 0.74 cm 3 demonstrated superior local tumor control or tumor shrinkage after GKS. However, this finding could be affected by inaccuracies associated with volumetry and segmentation of smaller tumors.
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Discussion
This study demonstrated an early (< 30 days after GKS) tumor volume reduction in 64 (47.8%) of the 134 tumors measured (Fig. 3) . The lesions that were more likely to be reduced in volume were carcinoma types that are typically viewed as "radiation sensitive," such as breast carcinomas (70%) and NSCLCs (46.4%).
Some of the tumors decreased quite significantly in volume. Of the tumors that decreased, the maximum decrease in tumor volume was 90% and the mean volume decrease was 41.7%. In general, tumor volume reduction rates varied very little as a function of initial tumor volume (Fig.  2) . Although not assessed in this particular study, such vol- ume reduction could allow improvements in neurological symptoms (such as headache) or deficits (such as weakness) and may facilitate a faster reduction in corticosteroid use. If we consider short-term local control as either decreased or stable volume, we achieved a tumor control rate of 88.8% of the lesions measured (119 of 134). Sixty-two (52%) of these 119 lesions were previously treated us ing WBRT, and 50 (42%) with some type of chemotherapy. Overall, the lesions that showed better local tumor control after GKS were NSCLCs and breast carcinomas.
Among the 15 lesions (11.2%) that increased in volume, 9 (60%) were melanomas. This finding is consistent with the fact that melanomas are relatively radiation "insensitive." 3, 11, 20 It may also be true that the follow-up period was too short to observe any beneficial effect in terms of tumor control from the GKS. The results suggest that for radiation-insensitive tumors such as melanomas, it may be beneficial to deliver a higher dose through radiosensitizing agents. However, even traditionally radiation-insensitive metastatic tumors such as melanomas and renal cell carcinomas are generally controlled using SRS, but tumor shrinkage may take longer than 30 days. This study has a number of limitations. For instance, the study does not assess to what degree early tumor reduction translates into long-term, durable tumor reduction or control. Also, there are inherent inaccuracies with tumor volumetry and tumor segmentation of any intracranial lesion (such as tumors, arteriovenous malformations, and others).
Nevertheless, this study shows that many brain metastases following GKS will demonstrate significant volume reduction within the first 30 days after such treatment. Such volume reduction may facilitate improvements in patient symptoms and neurological deficits. It may also enable corticosteroids to be tapered off more quickly. 5 In this study, we have not systematically examined the reduction of steroids in patients that demonstrated early metastatic tumor shrinkage. It is our current treatment algorithm to give patients with metastatic disease 1 dose of dexamethasone at the time of their GKS. Unless a patient has evidence on MR imaging of a T2-weighted signal abnormality around a metastatic lesion and clinical symptoms attributable to the peritumoral edema, we do not place patients on a regimen of corticosteroids. If a patient has edema on MR imaging and is symptomatic from it, we do administer steroids to him or her. Anecdotally, we have been able to quickly taper off steroids when a dramatic volume reduction occurs following radiosurgery. Of course, there are additional medical and oncological uses for steroids in cancer patients, and in a diverse group of Stage 4 cancer patients, some continue to take steroids for reasons other than central nervous systemrelated edema. At 6 months following treatment, the Radiation Therapy Oncology Group 9508 study showed a decrease in steroid use in patients receiving SRS and WBRT compared with those receiving WBRT alone. 1 This effect could be related to improved volume reduction of tumors with the addition of radiosurgery.
Moreover, in those patients in whom GKS and WBRT are planned treatments, GKS should be considered before WBRT because of its potential to induce early tumor volume reduction. Such volume reduction following GKS may be realized even before the typical length of time for completion of WBRT and the preparatory work of scheduling, consultation, and CT simulation associated with traditional radiation therapy.
Conclusions
Gamma Knife surgery provided early tumor shrinkage in 47.8% of the lesions measured in this patient population. Breast carcinoma and NSCLC were the histopathological subtypes that demonstrated the highest rate of early volume reduction. Melanoma brain metastases tended to respond less well, perhaps due to their relative radioresistant nature. As a result of the early volume reduction demonstrated by many brain metastases following single-session radiosurgery, one should consider performing GKS before WBRT when both treatment modalities are planned.
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